Guru Fundamental Report for HIMS

Validea's guru fundamental report indicates that HIMS & HERS HEALTH INC (HIMS) receives a 75% rating based on their Small-Cap Growth Investor model, which is based on the Motley Fool's published strategy. The rating is driven by strong fundamentals and price performance, with the stock passing key criteria such as profit margin, relative strength, and insider holdings; however, it fails tests related to cash and cash equivalents, the Fool Ratio, average shares outstanding, sales, and daily dollar volume.

Analysis

HIMS & HERS HEALTH INC (HIMS), identified as a large-cap growth stock in the Biotechnology & Drugs industry, received a 75% rating from Validea's report using the Motley Fool's Small-Cap Growth Investor strategy. This score, while indicating several fundamental strengths, falls short of the 80% threshold for "some interest" by this specific model, suggesting a mixed assessment. The evaluation passed numerous criteria, including profit margin, relative strength, year-over-year sales and EPS growth, insider holdings, cash flow from operations, profit margin consistency, R&D as a percentage of sales, inventory to sales, accounts receivable to sales, long-term debt/equity ratio, and current stock price. However, HIMS failed on metrics including cash and cash equivalents, "The Fool Ratio" (P/E to Growth), average shares outstanding, and income tax percentage. Notably, failures on "Sales" and "Daily Dollar Volume" might be attributable to HIMS's large-cap status potentially exceeding the typical parameters or thresholds for a small-cap focused model, rather than necessarily indicating inherent weakness in these areas for a company of its actual scale. This mixed assessment underscores a generally sound operational profile against specific concerns in liquidity, valuation purity by this model's standards, and its fit within this particular small-cap strategy's framework.

Key Decisions for Investors

• Investors should scrutinize HIMS's balance sheet, particularly its cash and cash equivalents, and independently assess its valuation given the failure on 'The Fool Ratio', despite generally positive operational metrics reported by the model.
• Consider that the 75% rating and some 'FAIL' criteria, such as absolute 'Sales' and 'Daily Dollar Volume', originate from a small-cap focused model being applied to a large-cap stock, which may influence the direct applicability of these specific flags for large-cap investment theses.
• Further due diligence should involve comparing HIMS against its large-cap growth peers using relevant industry benchmarks and valuation models to gain a more contextually appropriate perspective on its investment merits beyond this specific small-cap screen.